-
-
-
-
Description
- using a variant of histatins, which are naturally occurring cationic peptides in saliva
-
Activity
- Antifungal(fungal cell membrane,mitochondrion)
-
Medical use
- chronic Pseudomonas aeruginosa infections
-
Stage of Development
- Phase I
-
-
Company
- Demgen and Dow Pharmaceutical Sciences;licensed to the Vancouver, Canada, company Pacgen
-
Target Organism
-
- Histatins manifest an in vivo IC50 value of approximately 1.4 μM
-
Reference
-
- Histatins: antimicrobial peptides with therapeutic potential. J. Pharm. Pharmacol. (2004).(PMID: 15025852)